Point of care detection of HPV in saliva

唾液中 HPV 的护理点检测

基本信息

  • 批准号:
    10761543
  • 负责人:
  • 金额:
    $ 32.97万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-12 至 2024-09-11
  • 项目状态:
    已结题

项目摘要

Expanded point-of-care (POC) screening and monitoring options for detection of disease biomarkers from easily collectable specimens such as saliva are needed to reduce the incidence and mortality rates of debilitating diseases and enhance the resilience of the medical system, and improve care. InnoTech Precision Medicine with Massachusetts Institute of Technology is working to develop an innovative diagnostic platform that can be used for POC screening and monitoring of disease biomarkers. In our initial proof-of-concept, we are developing a POC test for detection of high-risk HPV in saliva. HPV is a viral infection that causes most Oropharyngeal squamous cell carcinoma (OPSCC) cases. Recent studies have demonstrated that HPV can be detected in saliva from patients with OPSCC. Currently, the initial screening and diagnosis of OPSCC is done at the late symptomatic stage based on symptoms that are often mild and can mimic less serious conditions such as cold or sore throat, delaying diagnosis and treatment. DNA tests for HPV are most often based on RT-PCR detection of the viral genetic material from serum or saliva that is collected and sent to central laboratories. RT-PCR-based tests rely on the amplification and detection of viral genetic material. These tests have long actionable turn- around-time, and high cost. Thus, there are no rapid, accurate and low-cost tests for routine monitoring of high- risk groups (i.e., young, sextually active, multiple partner) and monitoring of response to therapy and recurrence. Thus, a POC test for non-invasive monitoring of HPV in saliva during well-being exams can have a significant impact and save lives. Our objective is to develop a rapid, easy-to-use prototype for the detection of HPV in saliva based on the combination of biochemical signal amplification with CRISPR-Cas 12 electrochemical readout and our proprietary robust, accurate and low-cost gold-leaf electrodes. Utilizing our proprietary gold-leaf electrode along with a CRISPR-Cas12 assay for sensitive and specific electrochemical detection of target nucleic acid (NA) biomarkers, we have already demonstrated the detection of HPV 18 with plasmid DNA as well as in patient specimen. Our overall objective for this proposal is to develop a reproducible process for processing of saliva and develop a prototype electrochemical biosensor for the multiplex detection of HPV 16 and HPV 18 along with a reference gene to ensure accurate test results. To accomplish this goal, we will first develop a workflow for spatial multiplexing of our gold leaf electrodes for detection of HPV16, HPV 18 and an optimal reference gene. We will then verify this multiplexed test initially with plasmid DNA, and then with saliva specimens. We anticipate that combining easy-to-fabricate spatially multiplexed electrodes with CRISPR- Cas12a for the detection of a specific nucleic acid sequence will enable our Phase II development, regulatory approval and commercialization of a point-of-need technology that can be scaled and manufactured for accurate, easy-to-use and low-cost point-of-need testing and to reduce the burden of HPV infection and OPSCC.
扩大床旁(POC)筛查和监测选项,用于检测疾病生物标志物, 需要可收集的样本,如唾液,以减少衰弱性疾病的发病率和死亡率。 加强医疗系统的复原力,并改善护理。InnoTech精准医疗 与马萨诸塞州理工学院正在努力开发一个创新的诊断平台,可以 用于POC筛查和疾病生物标志物监测。在我们最初的概念验证中,我们正在开发 POC测试用于检测唾液中的高危HPV。HPV是一种病毒感染, 鳞状细胞癌(OPSCC)病例。最近的研究表明,HPV可以在 口腔鳞状细胞癌患者的唾液目前,OPSCC的初步筛查和诊断是在晚期进行的。 症状阶段,症状通常很轻微,可以模仿不太严重的情况,如感冒 或咽喉痛,延误诊断和治疗。HPV的DNA检测通常基于RT-PCR检测 收集并送往中心实验室的血清或唾液中的病毒遗传物质。基于RT-PCR 测试依赖于病毒遗传物质的扩增和检测。这些测试有很长的可操作性- 时间长,成本高。因此,没有快速、准确和低成本的检测方法用于常规监测高血压。 风险组(即,年轻、性活跃、多性伴)和监测对治疗的反应和复发。 因此,在健康检查期间用于唾液中HPV的非侵入性监测的POC测试可以具有显著的 影响和拯救生命。我们的目标是开发一种快速,易于使用的原型,用于检测HPV, 基于生物化学信号放大与CRISPR-Cas 12电化学的组合的唾液 读数和我们专有的坚固、准确和低成本的金叶电极。利用我们专有的金叶 电极沿着CRISPR-Cas 12测定用于靶核酸的灵敏和特异性电化学检测 酸性(NA)生物标志物,我们已经证明了用质粒DNA检测HPV 18以及在 病人标本我们提出这项建议的总体目标是开发一种可重复的工艺, 唾液,并开发用于HPV 16和HPV 18多重检测的原型电化学生物传感器 沿着参考基因以确保准确的测试结果。为了实现这一目标,我们将首先开发一个 我们的金箔电极用于检测HPV 16、HPV 18的空间多路复用的工作流程, 参考基因然后,我们将首先用质粒DNA,然后用唾液来验证这种多重测试 标本我们预计,将易于制造的空间多路复用电极与CRISPR- Cas 12 a用于检测特定的核酸序列将使我们的II期开发、调控 批准和商业化的一个点的需要的技术,可以规模和制造的准确, 易于使用和低成本的需求点检测,并减少HPV感染和OPSCC的负担。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROYA KHOSRAVI-FAR其他文献

ROYA KHOSRAVI-FAR的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROYA KHOSRAVI-FAR', 18)}}的其他基金

A multimodal platform for Oral screening of COVID-19
用于 COVID-19 口腔筛查的多模式平台
  • 批准号:
    10665346
  • 财政年份:
    2022
  • 资助金额:
    $ 32.97万
  • 项目类别:
A multimodal platform for Oral screening of COVID-19
用于 COVID-19 口腔筛查的多模式平台
  • 批准号:
    10266378
  • 财政年份:
    2020
  • 资助金额:
    $ 32.97万
  • 项目类别:
Tumor Selective Apoptosis by TRAIL
TRAIL 肿瘤选择性凋亡
  • 批准号:
    7837392
  • 财政年份:
    2009
  • 资助金额:
    $ 32.97万
  • 项目类别:
Tumor Selective Apoptosis by TRAIL
TRAIL 肿瘤选择性凋亡
  • 批准号:
    7930578
  • 财政年份:
    2009
  • 资助金额:
    $ 32.97万
  • 项目类别:
Tumor Selective Apoptosis by TRAIL
TRAIL 肿瘤选择性凋亡
  • 批准号:
    7743314
  • 财政年份:
    2009
  • 资助金额:
    $ 32.97万
  • 项目类别:
Novel Strategies for Treatment of Myeloproliferative Disorders
治疗骨髓增殖性疾病的新策略
  • 批准号:
    7670523
  • 财政年份:
    2008
  • 资助金额:
    $ 32.97万
  • 项目类别:
Novel Strategies for Treatment of Myeloproliferative Disorders
治疗骨髓增生性疾病的新策略
  • 批准号:
    8271290
  • 财政年份:
    2008
  • 资助金额:
    $ 32.97万
  • 项目类别:
Novel Strategies for Treatment of Myeloproliferative Disorders
治疗骨髓增生性疾病的新策略
  • 批准号:
    8092728
  • 财政年份:
    2008
  • 资助金额:
    $ 32.97万
  • 项目类别:
Novel Strategies for Treatment of Myeloproliferative Disorders
治疗骨髓增生性疾病的新策略
  • 批准号:
    7523599
  • 财政年份:
    2008
  • 资助金额:
    $ 32.97万
  • 项目类别:
Novel Strategies for Treatment of Myeloproliferative Disorders
治疗骨髓增生性疾病的新策略
  • 批准号:
    7846141
  • 财政年份:
    2008
  • 资助金额:
    $ 32.97万
  • 项目类别:

相似海外基金

CAREER: Biochemical and Structural Mechanisms Controlling tRNA-Modifying Metalloenzymes
职业:控制 tRNA 修饰金属酶的生化和结构机制
  • 批准号:
    2339759
  • 财政年份:
    2024
  • 资助金额:
    $ 32.97万
  • 项目类别:
    Continuing Grant
Leveraging releasable aryl diazonium ions to probe biochemical systems
利用可释放的芳基重氮离子探测生化系统
  • 批准号:
    2320160
  • 财政年份:
    2023
  • 资助金额:
    $ 32.97万
  • 项目类别:
    Standard Grant
Diurnal environmental adaptation via circadian transcriptional control based on a biochemical oscillator
基于生化振荡器的昼夜节律转录控制的昼夜环境适应
  • 批准号:
    23H02481
  • 财政年份:
    2023
  • 资助金额:
    $ 32.97万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Systematic manipulation of tau protein aggregation: bridging biochemical and pathological properties
tau 蛋白聚集的系统操作:桥接生化和病理特性
  • 批准号:
    479334
  • 财政年份:
    2023
  • 资助金额:
    $ 32.97万
  • 项目类别:
    Operating Grants
Converting cytoskeletal forces into biochemical signals
将细胞骨架力转化为生化信号
  • 批准号:
    10655891
  • 财政年份:
    2023
  • 资助金额:
    $ 32.97万
  • 项目类别:
Enhanced Biochemical Monitoring for Aortic Aneurysm Disease
加强主动脉瘤疾病的生化监测
  • 批准号:
    10716621
  • 财政年份:
    2023
  • 资助金额:
    $ 32.97万
  • 项目类别:
Biochemical Mechanisms for Sustained Humoral Immunity
持续体液免疫的生化机制
  • 批准号:
    10637251
  • 财政年份:
    2023
  • 资助金额:
    $ 32.97万
  • 项目类别:
Structural and biochemical investigations into the mechanism and evolution of soluble guanylate cyclase regulation
可溶性鸟苷酸环化酶调节机制和进化的结构和生化研究
  • 批准号:
    10604822
  • 财政年份:
    2023
  • 资助金额:
    $ 32.97万
  • 项目类别:
Chemical strategies to investigate biochemical crosstalk in human chromatin
研究人类染色质生化串扰的化学策略
  • 批准号:
    10621634
  • 财政年份:
    2023
  • 资助金额:
    $ 32.97万
  • 项目类别:
Examination of risk assessment and biochemical assessment of fracture development focusing on the body composition of patients with rheumatoid arthritis
关注类风湿性关节炎患者身体成分的骨折发生风险评估和生化评估检查
  • 批准号:
    22KJ2600
  • 财政年份:
    2023
  • 资助金额:
    $ 32.97万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了